Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.
Tessellate BIO is a biotechnology business in the preclinical stage that focuses on advanced Synthetic Lethality techniques.
Mariana Oncology is a biotechnology research industry.
Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.
Complement Therapeutics operates as a preclinical stage company.
Amphista Therapeutics operates as a biopharmaceutical company.
Inversago Pharma is a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics.
Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.
Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.
NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.
Oxular is a medical device startup dedicated to revolutionizing the way we measure ocular surface topography.
CoviCept Therapeutics is focused on the development of a small molecule that inhibits the replication and spread of RNA viruses.
OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.
Gotham Therapeutics is discovering a novel drug class targeting the epitranscriptomics machinery.
KaNDy Therapeutics is a clinical-stage company focused on optimizing the potential of NT-814.
Escalier Biosciences BV is a privately held biopharmaceutical company.
Prexton Therapeutics has the mission to develop innovative drugs to improve the quality of life.
Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options.
At Akarna, our mission is to develop best-in-class treatments for NASH and other chronic liver diseases
Ario Pharma is focused on the development of drugs for the treatment of respiratory indications.
Dezima Pharma develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia.
Forbion Capital Partners has invested in 122 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Forbion Capital Partners's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Biopharma. The firm invests across 12 different industry categories.
Among tracked funding rounds, Mariana Oncology received $175.0M in a Series B round. Forbion Capital Partners's total known invested capital is $9.0B.
Forbion Capital Partners's average investment size is $95.7M across its portfolio of 122 companies.
Recent Forbion Capital Partners portfolio additions include Rampart Bioscience, Tessellate BIO, Mariana Oncology, Dualyx, Complement Therapeutics. These companies were founded in 2020 or later.